NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)Business Wire • 06/08/21
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with CautionBenzinga • 06/04/21
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare ConferenceBusiness Wire • 06/04/21
Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 06/03/21
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: ReutersBenzinga • 06/03/21
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript)Seeking Alpha • 06/02/21
Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural MesotheliomaBenzinga • 06/02/21
Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic DiseasesBusiness Wire • 06/02/21
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural MesotheliomaBusiness Wire • 06/02/21
Bristol-Myers Squibb: Investment Case Getting Better And Better - A Great Time To BuySeeking Alpha • 05/30/21
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1Business Wire • 05/27/21
Bristol Myers Squibb to Take Part in Bernstein's 37th Annual Strategic Decisions ConferenceBusiness Wire • 05/26/21
Bristol-Myers Squibb Company (BMY) Management Presents at 2021 UBS Global Healthcare Virtual Conference (Transcript)Seeking Alpha • 05/25/21
Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 AntibodiesBenzinga • 05/25/21